IV期alk阳性肺腺癌:克唑替尼治疗7.5年完全缓解

Annals of hematology & oncology Pub Date : 2021-05-20 DOI:10.26420/annhematoloncol.2021.1350

D. Rouabhia, R. Audet, P. Desmeules, C. Labbé

{"title":"IV期alk阳性肺腺癌:克唑替尼治疗7.5年完全缓解","authors":"D. Rouabhia, R. Audet, P. Desmeules, C. Labbé","doi":"10.26420/annhematoloncol.2021.1350","DOIUrl":null,"url":null,"abstract":"Multiple lines of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) are recommended for the treatment of ALK-positive Non-Small Cell Lung Cancer (NSCLC). This article provides an unusual case report of a 33-year-old male patient with a 91-month Progression-Free Survival (PFS) on a first-generation TKI, crizotinib.","PeriodicalId":72219,"journal":{"name":"Annals of hematology & oncology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Stage IV ALK-Positive Lung Adenocarcinoma: 7.5-Year Complete Remission with Crizotinib\",\"authors\":\"D. Rouabhia, R. Audet, P. Desmeules, C. Labbé\",\"doi\":\"10.26420/annhematoloncol.2021.1350\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Multiple lines of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) are recommended for the treatment of ALK-positive Non-Small Cell Lung Cancer (NSCLC). This article provides an unusual case report of a 33-year-old male patient with a 91-month Progression-Free Survival (PFS) on a first-generation TKI, crizotinib.\",\"PeriodicalId\":72219,\"journal\":{\"name\":\"Annals of hematology & oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-05-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of hematology & oncology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.26420/annhematoloncol.2021.1350\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of hematology & oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26420/annhematoloncol.2021.1350","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

多系间变性淋巴瘤激酶(ALK)酪氨酸激酶抑制剂(TKIs)被推荐用于治疗ALK阳性的非小细胞肺癌(NSCLC)。这篇文章提供了一个不寻常的病例报告，33岁的男性患者在第一代TKI，克唑替尼的91个月无进展生存期(PFS)。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Stage IV ALK-Positive Lung Adenocarcinoma: 7.5-Year Complete Remission with Crizotinib

Multiple lines of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKIs) are recommended for the treatment of ALK-positive Non-Small Cell Lung Cancer (NSCLC). This article provides an unusual case report of a 33-year-old male patient with a 91-month Progression-Free Survival (PFS) on a first-generation TKI, crizotinib.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of hematology & oncology

自引率

0.00%

发文量